Publikationen (105) Publikationen von JOSÉ ANTONIO HERRERO CALVO

2023

  1. Epidemiology of Fabry disease in patients in hemodialysis in the Madrid community

    Nefrologia, Vol. 43, Núm. 4, pp. 435-441

  2. Reply to the letter to the editor regarding “Nonvalvular atrial fibrillation in patients undergoing chronic haemodialysis, should we anticoagulate?”

    Nefrologia

2022

  1. Nonvalvular atrial fibrillation in patients undergoing chronic hemodialysis. Should dialysis patients with atrial fibrillation receive oral anticoagulation?

    Nefrologia, Vol. 42, Núm. 6, pp. 633-644

  2. The relevance of geriatric assessments on the association between chronic kidney disease stages and mortality among older people: A secondary analysis of a multicentre cohort study

    Age and Ageing, Vol. 51, Núm. 7

2021

  1. Association between coffee consumption and total dietary caffeine intake with cognitive functioning: cross-sectional assessment in an elderly Mediterranean population

    European Journal of Nutrition, Vol. 60, Núm. 5, pp. 2381-2396

  2. Control of phosphorus and prevention of fractures in the kidney patient

    Nefrologia, Vol. 41, Núm. 1, pp. 7-14

  3. Estimating hospital inpatient cost-savings with sucroferric oxyhydroxide in patients on chronic hemodialysis in five European countries: a cost analysis

    Journal of Medical Economics, Vol. 24, Núm. 1, pp. 1240-1247

  4. Hemodialysis Centers Guide 2020

    Nefrologia, Vol. 41, pp. 1-77

2020

  1. Association between kidney function, nutritional status and anthropometric measures in older people

    BMC Geriatrics, Vol. 20

  2. Chronic kidney disease in the context of multimorbidity patterns: The role of physical performance

    BMC Geriatrics, Vol. 20

  3. Initiating renal replacement therapy through incremental haemodialysis: Protocol for a randomized multicentre clinical trial

    Trials, Vol. 21, Núm. 1

2019

  1. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

    The Lancet, Vol. 393, Núm. 10184, pp. 1937-1947

  2. Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy

    Medicina Clinica, Vol. 153, Núm. 2, pp. 47-55

  3. Impact of first year renal replacement therapy on the hospital admissions of a regional public health system

    Nefrologia, Vol. 39, Núm. 6, pp. 653-663

2017

  1. Testosterone deficiency in dialysis patients: Difference between dialysis techniques

    Nefrologia, Vol. 37, Núm. 5, pp. 526-530

2016

  1. Serum biomarkers in uncontrolled no heart-beating donors may identify kidneys that will never work after transplantation

    Journal of Nephrology, Vol. 29, Núm. 1, pp. 119-127

  2. The Spanish Renal Registry: 2013 report and evolution from 2007-2013

    Nefrologia, Vol. 36, Núm. 2, pp. 97-120

2015

  1. Clinical evolution of chronic renal patients with HIV infection in replacement therapy

    Nefrologia, Vol. 35, Núm. 5, pp. 457-464

  2. Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis

    Health Economics Review, Vol. 5, Núm. 1

  3. Cost-effectiveness analysis of lanthanum carbonate versus sevelamer hydrochloride in the treatment of hyperphosphatemia in patients with end-stage renal disease in Spain

    Pharmacoeconomics - Spanish Research Articles, Vol. 12, Núm. 1, pp. 11-22